28 July 2023 in Multiple Sclerosis and Related Disorders
10 November 2026 in CNS Neuroscience & Therapeutics
Background: Chronic pain has been linked to neurological and psychiatric disorders, yet the metabolic mechanisms driving this association remain unclear. Methods: Leveraging data from 174,630 UK Biobank participants, we examined associations of 251 plasma metabolites with chronic pain across seven body sites and constructed a metabolic signature using elastic net regression. Cox proportional hazards models were applied to explore the associations of chronic pain and the metabolic signature with 10 incident brain disorders. For outcomes with significant associations, we evaluated genetic causality of the identified metabolites using Mendelian randomization (MR). Mediation analyses were conducted to evaluate inflammatory pathways involving eight markers, such as platelet count and C‐reactive protein. Results: Most metabolites were significantly associated with chronic pain (FDR‐corrected p < 0.05), with 88 metabolites forming a metabolic signature. During a median follow‐up of 15.6 years, an increasing number of chronic pain sites and a higher metabolic signature were associated with increased risks of depression, anxiety, and ischemic stroke (IS). Systemic inflammation, particularly platelet and leukocyte counts, partially mediated the effect of the metabolic signature on depression (4.33%) and IS (9.52%). Furthermore, MR analyses suggested potential causal roles for several metabolites in these outcomes, such as docosahexaenoic acid (DHA). Conclusion: Our findings highlight the pivotal role of metabolic dysregulation in the connection between chronic pain and brain disorders. These results offer valuable insights into inflammation‐mediated mechanisms and identify potential metabolic biomarkers for prevention.